Scinai Immunotherapeutics Ltd. (SCNI)
NASDAQ: SCNI · Real-Time Price · USD
0.630
+0.046 (7.83%)
Apr 29, 2026, 1:02 PM EDT - Market open

Scinai Immunotherapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2016
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 2020 - 2016
Net Income
-8.314.8-6.5-5.8-8.21
Upgrade
Depreciation & Amortization
1.421.650.510.560.47
Upgrade
Asset Writedown & Restructuring Costs
---0.21-
Upgrade
Stock-Based Compensation
0.30.681.141.62.76
Upgrade
Other Operating Activities
0.39-13.57-3.74-4.11-3.15
Upgrade
Change in Accounts Receivable
0.01-0.08--0.06
Upgrade
Change in Accounts Payable
0.03-0.16-0.15-0.180
Upgrade
Change in Other Net Operating Assets
0.120.35-0.650.450.64
Upgrade
Operating Cash Flow
-6.03-6.34-9.38-7.27-7.43
Upgrade
Capital Expenditures
-0.02-0.01-0.64-0.84-0.14
Upgrade
Investing Cash Flow
-0.02-0.01-0.64-0.84-0.14
Upgrade
Issuance of Common Stock
5.771.441.096.7821.43
Upgrade
Other Financing Activities
-2---
Upgrade
Financing Cash Flow
5.773.441.096.7821.43
Upgrade
Foreign Exchange Rate Adjustments
0-0.01-0.27-1.980.58
Upgrade
Net Cash Flow
-0.28-2.92-9.21-3.314.44
Upgrade
Free Cash Flow
-6.06-6.35-10.02-8.1-7.57
Upgrade
Free Cash Flow Margin
-461.86%-964.59%---
Upgrade
Free Cash Flow Per Share
-2.59-7.87-25.65-42.97-53.60
Upgrade
Cash Interest Paid
-0.140.830.92-
Upgrade
Levered Free Cash Flow
-3.33-3.82-8.28-5.52-2.71
Upgrade
Unlevered Free Cash Flow
-3.1-2.93-5.9-5.52-2.71
Upgrade
Change in Working Capital
0.160.11-0.80.270.7
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.